On May 23, 2022, Agios Pharmaceuticals, Inc. (the Company) entered into a consulting agreement (the Consulting Agreement) with Bruce Car, Ph.D., effective as of August 1, 2022 (the Effective Date), which is the date following the effective date of Dr. Car's resignation as the Company's chief scientific officer. Pursuant to the Consulting Agreement, Dr. Car has agreed to assist the Company with the transition of the research and discovery science and to provide such other services as may be requested by the Company from time to time (which services will not exceed 10 hours per week).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.12 USD | -1.12% |
|
-4.64% | +93.62% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+93.62% | 247.59Cr | |
+15.20% | 12TCr | |
+19.67% | 11TCr | |
+18.95% | 2.65TCr | |
-23.86% | 1.94TCr | |
-19.03% | 1.62TCr | |
-20.90% | 1.54TCr | |
-46.14% | 1.52TCr | |
+63.85% | 1.49TCr | |
+4.49% | 1.35TCr |
- Stock Market
- Equities
- AGIO Stock
- News Agios Pharmaceuticals, Inc.
- Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022